Regeneron Pharmaceuticals, Inc. v. Mylan Pharmaceuticals Inc.

Opinion

Case: 23-1395 Document: 61 Page: 1 Filed: 07/09/2024

NOTE: This order is nonprecedential.

United States Court of Appeals for the Federal Circuit ______________________

REGENERON PHARMACEUTICALS, INC., Appellant

v.

MYLAN PHARMACEUTICALS INC., CELLTRION, INC., APOTEX INC., Appellees ______________________

2023-1395, 2023-1396 ______________________

Appeals from the United States Patent and Trademark Office, Patent Trial and Appeal Board in Nos. IPR2021- 00880, IPR2021-00881, IPR2022-00257, IPR2022-00258, IPR2022-00298, IPR2022-00301. ______________________ ORDER The parties, having so agreed, IT IS ORDERED THAT: The above-captioned appeals are dismissed under Fed. R. App. P. 42(b) with each side to bear their own costs.

FOR THE COURT

July 9, 2024 Date

ISSUED AS A MANDATE: July 9, 2024